Arcutis Biotherapeutics ARQT 深 滬
已收盤 11-14 16:00:00 美东时间
25.00
+2.140
+9.36%
華盛通- 最 高25.20
- 今 開22.28
- 成交量 395.40万股
- 最 低 22.26
- 昨 收 22.86
- 總市值 30.00亿
- 52周最高 27.0793
- 市盈率 靜 --
- 換手率 3.29%
- 52周最低 10.21
- 委 比 -40.75%
- 總股本 1.20亿
- 歷史最高 40.88
- 量 比 1.77
- 振 幅 12.86%
- 歷史最低 1.76
- 每 手 1
- 風險率 3.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest
Arcutis Biotherapeutics Inc's (NYSE:ARQT) short interest as a percent of float ...
11-14 03:00
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics has expanded its rare disease pipeline, with four QTORIN™-derived candidates targeting serious, rare skin diseases without FDA-approved therapies. Top-line results for the Phase 2 TOIVA trial (QTORIN™ rapamycin for cutaneous venous malformations) are expected mid-December 2025, while Phase 3 SELVA trial results (microcystic lymphatic malformations) are anticipated in Q1 2026. QTORIN™ rapamycin is also being developed for cli...
11-11 12:30
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) awarded 51,000 restricted stock units to six new employees under its 2022 Inducement Plan. The awards, granted on November 3, 2025, vest over four years, with 25% vesting annually. The company provided the information in compliance with Nasdaq Listing Rule 5635(c)(4). Arcutis focuses on创新 in免疫皮肤病学, with a portfolio of approved treatments for inflammatory skin diseases.</p>
11-07 21:00
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
美股牛股 | CCJ飙升23%，与美国政府签署投资达800亿美元核能发电协议；诺基亚大涨22%
CCJ飙升23%，与美国政府签署投资达800亿美元核能发电协议；诺基亚大涨22%，公司获英伟达10亿美元股权投资；阿吉赛斯大涨22%，财报表现强劲并上调收入指引>>
10-29 16:52
快讯 | Arcutis生物治疗公司：Jefferies将目标价从23美元上调至31美元
Arcutis Biotherapeutics Inc : Jefferies Raises Target Price to $31 From $23
10-29 12:21
Arcutis Biotherapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
10-29 05:12
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
Arcutis Biotherapeutics shares are trading higher after the company reported be...
10-28 23:01
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
10-28 22:14
Arcutis Biotherapeutics Q3 EPS $0.06 Beats $(0.10) Estimate, Sales $99.219M Beat $86.978M Estimate
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.10) by 161.86 percent. This is a 118.18 percent increase over losses of $(0.33) per
10-28 20:31
